Boehringer In­gel­heim to cash out Hik­ma stake; Breast can­cer biotech sets terms for IPO

Boehringer In­gel­heim is of­fload­ing a ma­jor chunk of its hold­ing in Hik­ma, propos­ing to sell 28 mil­lion out of 40 mil­lion shares of the Lon­don-list­ed drug­mak­er. The stake is val­ued at near­ly £1 bil­lion, and Hik­ma has com­mit­ted to buy­ing no more than £295 mil­lion of it — which would amount to 4.99% of its stock’s val­ue at the time the deal was un­veiled. The Ger­man phar­ma gi­ant had ob­tained these shares when it sold Rox­ane Lab­o­ra­to­ries to Hik­ma in 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.